Skip to main content
. 2024 Nov 12;15:1480676. doi: 10.3389/fimmu.2024.1480676

Figure 4.

Figure 4

Risk of achieving inflammatory activity at baseline (A), 3 months (B), and 6 months (C) of ocrelizumab follow-up. Number (N) of patients with sNFL values above (orange) or below (green) 10 pg/ml. OCR, ocrelizumab treatment; sNfL, serum neurofilament light chains; NEDA-3, patients free of disease activity at 12 months of ocrelizumab initiation (n = 85); INFL, patients with new relapses and/or radiological activity during follow-up (n = 20); OR, odds ratio; CI, confidence interval.